By Davit Kirakosyan Insider buying activities are important for investors to pay attention to. Insiders buy for one reason – because they feel the stock is too cheap, although that...
Investing.com – U.S. stocks were higher after the close on Tuesday, as gains in the Technology, Basic Materials and Consumer Goods sectors led shares higher. At the close in NYSE,...
The past week was busy for the biotech sector with several pipeline updates as the reporting cycle ended. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) won the FDA approval for...
Shares of clinical-stage biopharmaceutical company Zafgen, Inc. (NASDAQ:ZFGN) slumped 40.5% after the company announced that the FDA has placed a clinical hold on the...
Larimar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its cell penetrating peptide technology platform. The Company's protein replacement therapy platform is intended to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that are ineffective or have no treatments available. Its cell penetrating peptide (CPP) technology platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company's lead product candidate, CTI-1601, is a recombinant fusion protein intended to deliver human frataxin (FXN), an essential protein to the mitochondria of patients with Friedreich’s ataxia. CTI-1601 is in a Phase I clinical program.
|Average||5.500 (+75.16% Upside)|
|No. of Analysts||2|